Journal of Translational Medicine · 2023 · 13 citations · 75 references
Life SciencesCell BiologyImmunologyImmunopharmacologyImmunotherapyInnate ImmunityAntiretroviral TherapyAntiviral ImmunityCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsNatural Killer Cell BiologyNatural Killer Cell TherapyCd4 Positive T CellsCd4 T Cell ActivationCd4 T-cell DepletionCheckpoint Inhibitor CombinationsInhibitory Killer Cell Immunoglobulin-like ReceptorsNatural Killer Cell Checkpoint RegulationNatural Killer Cell Receptor-ligand InteractionsViral Replication Control
Abstract Background Combination antiretroviral therapy (cART) has dramatically extended the life expectancy of people living with HIV-1 and improved their quality of life. There is nevertheless no cure for HIV-1 infection since HIV-1 persists in viral reservoirs of latently infected CD4 + T cells. cART does not eradicate HIV-1 reservoirs or restore cytotoxic natural killer (NK) cells which are dramatically reduced by HIV-1 infection, and express the checkpoint inhibitors NKG2A or KIR2DL upregulated after HIV-1 infection. Cytotoxic NK cells expressing the homing receptor CXCR5 were recently described as key subsets controlling viral replication. Methods We designed and evaluated the potency of “Natural killer activating Multimeric immunotherapeutic compleXes”, called as NaMiX, combining multimers of the IL-15/IL-15Rα complex with an anti-NKG2A or an anti-KIR single-chain fragment variable (scFv) to kill HIV-1 infected CD4 + T cells. The oligomerization domain of the C4 binding protein was used to associate the IL-15/IL-15Rα complex to the scFv of each checkpoint inhibitor as well as to multimerize each entity into a heptamer (α form) or a dimer (β form). Each α or β form was compared in different in vitro models using one-way ANOVA and post-hoc Tukey’s tests before evaluation in humanized NSG tg-huIL-15 mice having functional NK cells. Results All NaMiX significantly enhanced the cytolytic activity of NK and CD8 + T cells against Raji tumour cells and HIV-1 + ACH-2 cells by increasing degranulation, release of granzyme B, perforin and IFN-γ. Targeting NKG2A had a stronger effect than targeting KIR2DL due to higher expression of NKG2A on NK cells. In viral inhibition assays, NaMiX initially increased viral replication of CD4 + T cells which was subsequently inhibited by cytotoxic NK cells. Importantly, anti-NKG2A NaMiX enhanced activation, cytotoxicity, IFN-γ production and CXCR5 expression of NK cells from HIV-1 positive individuals. In humanized NSG tg-huIL-15 mice, we confirmed enhanced activation, degranulation, cytotoxicity of NK cells, and killing of HIV-1 infected cells from mice injected with the anti-NKG2A.α NaMiX, as compared to control mice, as well as decreased total HIV-1 DNA in the lung. Conclusions NK cell-mediated killing of HIV-1 infected cells by NaMiX represents a promising approach to support HIV-1 cure strategies.
75
Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
Jedd D. Wolchok, Vanna Chiarion‐Sileni, René González et al. · New England Journal of Medicine · 2017 · 5.4K citations · Full text
Pharmacy, Oncology, Pharmacotherapy +17
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
Nancie M. Archin, Abigail Liberty, Angela D. M. Kashuba et al. · Nature · 2012 · 1.2K citations
IL-15Rα Recycles and Presents IL-15 In trans to Neighboring Cells
Sigrid Dubois, Jennifer Mariner, Thomas A. Waldmann et al. · Immunity · 2002 · 889 citations · Full text